Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street - shutterstock_94127350
Stock Index Futures Slip on Growth Fears, U.S. JOLTs Report in Focus Barchart - Tue Jun 4, 4:39AM CDT

June S&P 500 E-Mini futures (ESM24) are down -0.36%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.34% this morning after weak manufacturing data raised concerns about the U.S. economic health,...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
PARA : 11.46 (+6.90%)
NVDA : 128.28 (+4.57%)
BA : 184.31 (-0.60%)
SAIC : 116.32 (-0.12%)
FANG : 206.93 (+0.99%)
DVN : 48.11 (+0.71%)
CRWD : 387.18 (+0.55%)
FERG : 189.97 (-0.45%)
PVH : 104.67 (+1.45%)
HPE : 20.67 (-2.13%)
Why Shares of Annexon Are Plummeting Thursday Motley Fool - Thu May 25, 2023

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

ISEE : 39.95 (+0.38%)
APLS : 35.41 (+1.23%)
ALPMY : 9.8050 (-0.15%)
ANNX : 4.80 (+5.04%)
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results Globe Newswire - Mon Aug 8, 2022

Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts...

ANNX : 4.80 (+5.04%)
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025 Globe Newswire - Mon Jul 11, 2022

Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and Eye...

ANNX : 4.80 (+5.04%)
Annexon Announces $130 Million Private Placement Financing Globe Newswire - Fri Jul 8, 2022

BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

ANNX : 4.80 (+5.04%)
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease Globe Newswire - Tue Jun 7, 2022

ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the...

ANNX : 4.80 (+5.04%)
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference Globe Newswire - Thu Jun 2, 2022

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

ANNX : 4.80 (+5.04%)
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings Globe Newswire - Wed Jun 1, 2022

BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

ANNX : 4.80 (+5.04%)
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results Globe Newswire - Mon May 9, 2022

Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts...

ANNX : 4.80 (+5.04%)
Annexon Biosciences to Participate in Upcoming May Investor Conferences Globe Newswire - Thu May 5, 2022

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...

ANNX : 4.80 (+5.04%)

Barchart Exclusives

It’s the Fourth of July: Drink Up With This Unusually Active SBUX Option Barchart - 17 minutes ago
BBQs are on the agenda for many Americans because it's the Fourth of July. If you happen to be considering your investments, an usually active Starbucks option on Wednesday looks ready for investors to drink up. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot